When a biotech company chooses to progress a molecule as a liquid injectable, it commits not only to a delivery format but also to a complex stability profile. In solution, the active ingredient is continuously exposed to factors that accelerate degradation and alter performance. These risks become more pronounced as development accelerates toward toxicology studies, clinical evaluation and eventual scale up. For companies operating under tight timelines and budgets, understanding these stability drivers early can prevent avoidable reformulation, manufacturing delays and regulatory setbacks.

The Challenges of Working with Liquid Injectables

• Access of Degradation Pathways

In terms of the key challenges associated with the complex stability profile of liquids, the primary challenge stems from the fact that a liquid environment gives degradation pathways constant access to the molecule. Whilst solid forms restrict molecular mobility, liquid formulations enable hydrolysis, oxidation, deamidation, aggregation and other reactions that proceed readily once the drug is hydrated. Even when the vial appears visually unchanged, subtle structural shifts may already be compromising potency or safety. This is particularly true for biologics, peptides and complex small molecules, which often carry chemically sensitive groups or higher order structures that only remain intact under tightly controlled conditions.

• Oxidation

Oxidation is one of the most common and problematic mechanisms affecting liquid injectables. Dissolved oxygen, oxygen ingress through container systems and reactive oxygen species generated during processing can all initiate unwanted reactions. These reactions may create impurities, reduce potency or alter the molecule’s conformation. The challenge for biotechs is that oxidation can occur gradually and unpredictably, making it difficult to identify root causes late in development. Mitigating oxidation requires thoughtful selection of antioxidants, careful control of dissolved oxygen during manufacturing and appropriate use of barrier materials in the primary packaging. Early identification of oxidation hot spots allows development teams to refine the formulation before process parameters become fixed.

• Hydrolysis

Hydrolysis presents a different but equally important concern. Water acts as both solvent and reactant, and labile chemical groups may cleave over time even at refrigerated temperatures. This is especially relevant for prodrugs, ester containing molecules and certain peptide sequences. The degradation rate often increases significantly with small variations in pH or temperature, meaning that stress studies must be designed to capture both the expected and the slightly unexpected conditions a product may encounter. For biotechs progressing rapidly through development milestones, establishing a comprehensive hydrolytic risk profile early reduces the likelihood of discovering problematic impurities after clinical material has already been manufactured.

• Biopharmaceuticals

Biopharmaceuticals introduce additional challenges in the form of aggregation, unfolding and other structural changes. Proteins in solution are sensitive to mechanical stress, temperature, pH, ionic strength and exposure to interfaces such as glass or silicone oil. Even small perturbations can cause reversible or irreversible aggregation, leading to subvisible particles or changes in biological activity. These risks become more prominent during fill finish operations and during storage. For companies developing their first injectable biologic, the interplay between formulation, process conditions and container materials can be unfamiliar territory. Robust analytical methods, including those sensitive to early signs of aggregation, are essential to maintaining control over the molecule’s behaviour in solution.

• Packaging Choices

Packaging choices can also significantly influence stability. Glass vials may interact with certain formulations, while plastic containers can leach trace compounds that alter degradation pathways. Rubber stoppers vary in extractables and oxygen permeability. Prefilled syringes introduce silicone oil that can affect sensitive proteins. Each decision in the container closure system affects the formulation’s long term performance. It is striking how often packaging is addressed late in development, only to reveal an incompatibility that forces reformulation or a switch in primary packaging. Integrating packaging evaluation into the earliest development stages helps biotechs avoid costly revisions.

• Temperature

Temperature is another critical variable. Many liquid injectables must be stored at low temperatures, yet temperature fluctuations during shipping and handling are common. Proteins may denature when frozen or thawed, while small molecules may degrade rapidly when exposed to elevated temperatures. Understanding how the formulation responds to excursions is just as important as defining the ideal storage range. Stability studies that simulate realistic handling conditions support more accurate shelf-life predictions and reduce surprises in clinical supply chains.

Stabilising Liquid Injectables

Avoiding these pitfalls requires a proactive and structured approach to design. The foundation is a comprehensive preformulation programme that interrogates the molecule’s intrinsic stability risks. By understanding how the molecule behaves across pH ranges, ionic strengths, temperatures and stress conditions, development teams can make informed decisions about excipients, manufacturing processes and packaging. This work defines the molecule’s tolerance limits before constraints tighten during scale up.

With these data in hand, formulation development becomes an exercise in deliberate control. Buffers must maintain pH within tight ranges. Antioxidants and chelators must be chosen based on demonstrated compatibility. Surfactants, tonicity agents and stabilisers must be justified scientifically rather than added reflexively. Small formulation adjustments can dramatically alter long term behaviour, and disciplined excipient selection ensures that complexity is added only where it truly benefits stability.

Manufacturing processes need equal attention. Agitation, filtration, heating steps and exposure to light can all influence stability. Filling processes introduce shear, pressure changes and interactions with vial surfaces. Headspace gas composition affects oxidation. A manufacturing process that is gentle on the molecule is just as important as the formulation itself. For biotechs transitioning from research scale to GMP production, this alignment between formulation and process is often where stability challenges first emerge, and the quality of the tech transfer becomes apparent.

Long term success also depends on considering real world storage and use conditions rather than only ideal conditions. A formulation that meets stability requirements in controlled environments but fails after routine handling is not commercially viable. Ensuring robustness across transport, clinical site storage and patient administration builds reliability into the product from the beginning.

Liquid injectable stability is a multi-variable challenge that demands scientific rigour, early intervention and cross functional collaboration. For biotechs moving at pace, the most effective strategy is to identify risks early and address them systematically, before the molecule progresses into stages where changes become costly or constrained. At Upperton, we work closely with development teams to bring clarity to these challenges, guiding each molecule through the complexity of the liquid environment so that when it reaches patients, its quality and performance remain uncompromised.